Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production

References

• Teitelbaum D, Meshorer M, Hirshfeld T, Sela M, Arnon R. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971; 1: 242–248
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol 1974; 3: 256–262
   Web of Science ®Google Scholar
• Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M. Copolymer 1 inhibits chronic relapsing allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP specific T cell responses. J Neuroimmunol 1996; 64: 209–217
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998; 91: 135–146
   PubMed Web of Science ®Google Scholar
• Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis—personal reflections. Immunol Lett 1996; 50: 1–15
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408–414
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, Spada V, Weiss W, Appel S, Rolak L, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 4: 533–539
   Google Scholar
• Stark Y. Expanded clinical trials of treatments for multiple sclerosis: Copolymer 1 (COP-1) treatment investigational new drug (IND) program. Ann Neurol 1994; 36: 114–115
   PubMed Web of Science ®Google Scholar
• Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113–121
   PubMed Web of Science ®Google Scholar
• Zhang M, Chan C, Vistica B, Hung V, Wiggert B, Gery I. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol 2000; 103: 189–194
   PubMed Web of Science ®Google Scholar
• Angelov DN, Waibel S, Guntinas-Lichius O, Lenzen M, Neiss WF, Tomov TL, Yoles E, Kipnis J, Schori H, Reuter A, et al. Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for ALS. Proc Natl Acad Sci USA 2003; 100: 4790–4795
   PubMed Web of Science ®Google Scholar
• Arnon R, Sela M. Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit 2003; 16: 412–421
   PubMed Web of Science ®Google Scholar
• Schlegel PG, Aharoni R, Chen Y, Chen J, Teitelbaum D, Arnon R, Sela M, Chao NJ. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T cell proliferative responses to major and minor histo-compatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. Proc Natl Acad Sci USA 1996; 93: 5061–5066
   PubMed Web of Science ®Google Scholar
• Aharoni R, Schlege lPG, Teitelbaum D, Roikhel-Karpov O, Chen Y, Arnon R, Sela M, Chao NJ. Studies on the mechanism and specificity of the synthetic copolymer GLAT on graft-versus-host disease. Immunol Lett 1997; 58: 79–87
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 inhibits manifestations of graft rejection. Transplantation 2001; 72: 598–605
   PubMed Web of Science ®Google Scholar
• Racke MK, Martin R, McFarland H, Fritz RB. Copolymer-1-induced inhibition of antigen-specific T cell activation: Interference with antigen presentation. J Neuroimmunol 1992; 37: 75–84
   PubMed Web of Science ®Google Scholar
• Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ, Brenner T, Arnon R, Sela M. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatability complex molecules on living antigen-presenting cells—specificity and promiscuity. Proc Natl Acad Sci USA 1994; 91: 4872–4876
   PubMed Web of Science ®Google Scholar
• Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc Natl Acad Sci USA 1998; 95: 12528–12531
   PubMed Web of Science ®Google Scholar
• Fridkis-Hareli M, Neveu JM, Robinson RA, Lane WS, Gauthier L, Wucherpfennig KW, Sela M, Strominger JL. Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol 1999; 162: 4697–4704
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Aharon iR, Fridkis-Hareli M, Arnon R, Sela M. Development of copolymer 1 (Copaxone) as a specific drug against multiple sclerosis. The decade of autoimmunity, Y Shoenfeld. Elsevier Science, Amsterdam 1999; 191–196
   Google Scholar
• Lando Z, Teitelbaum D, Arnon R. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 1979; 132: 2156–2160
   Google Scholar
• Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997; 94: 10821–10826
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Arnon R. T-suppressor hybridomas and IL-2 dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur J Immunol 1993; 23: 17–25
   PubMed Web of Science ®Google Scholar
• Vollmer T. Safety and tolerability of glatiramer acetate for injection (formerly known as copolymer 1) in the treatment of multiple sclerosis patients previously treated with interferon β-1b. Ann Neurol 1998; 44: 505
   Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against EAE by copolymer. Proc Natl Acad Sci USA 2000; 97: 11472–11477
   PubMed Web of Science ®Google Scholar
• Aharoni R, Meshorer A, Sela M, Arnon R. Oral treatment of mice with copolymer 1 (glatiramer acetate) results in accumulation of specific Th2 cells in the central nervous system. J Neuroimmunol 2002; 126: 58–68
   PubMed Web of Science ®Google Scholar
• Weiner HL. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 1999; 96: 3333–3335
   PubMed Web of Science ®Google Scholar
• Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+ CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005; 102: 6449–6454
   PubMed Web of Science ®Google Scholar
• Trentham D. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum 1982; 25: 911–916
   PubMed Web of Science ®Google Scholar
• Holmdahl R, Andersson M, Goldschmidt TJ, Gustafsson K, Jansson L, Mo JA. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev 1932; 118: 32
   Google Scholar
• Nabozny GH, David CS. The immunogenetic basis of collagen induced arthritis in mice: An experimental model for the rational design of immuno-modulatory treatments of rheumatoid arthritis. Adv Exp Med Biol 1994; 347: 55–63
   PubMedGoogle Scholar
• Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997; 61: 1861–1878
   PubMed Web of Science ®Google Scholar
• Stuart JM, Cremer MA, Townes AA, Kang AH. Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med 1982; 155: 1–16
   PubMed Web of Science ®Google Scholar
• Wooley PH, Luthra HS, Krco CJ, Stuart JM, David CS. Type II collagen-induced arthritis in mice. 1984. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen. Arthritis Rheum 1984; 27: 1010–1017
   PubMed Web of Science ®Google Scholar
• Trentham DE, Dynesius RA, David JR. Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Invest 1978; 62: 359–366
   PubMed Web of Science ®Google Scholar
• Holmdahl R, Klareskog L, Rubin K, Larsson E, Wigzell H. T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol 1985; 22: 295–306
   PubMed Web of Science ®Google Scholar
• Griffiths MM, Eichwald EJ, Martin JH, Smith CB, DeWitt CW. Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats. Arthritis Rheum 1981; 24: 781–789
   PubMed Web of Science ®Google Scholar
• Wooley PH, Luthra HS, Krco CJ, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981; 154: 688–700
   PubMed Web of Science ®Google Scholar
• Banerjee S, Haqqi TM, Luthra HS, Stuart JM, David CS. Possible role of V beta T cell receptor genes in susceptibility to collagen-induced arthritis in mice. J Exp Med 1988; 167: 832–839
   PubMed Web of Science ®Google Scholar
• Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998; 19: 37–44
   PubMedGoogle Scholar
• Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996; 26: 1511–1518
   PubMed Web of Science ®Google Scholar
• Doncarli A, Stasiuk L, Fournier C, Abehsira-Amar O. Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis. Eur J Immunol 1997; 27: 1451–1458
   PubMed Web of Science ®Google Scholar
• Joosten LA, Lubberts E, Durez P, Helse MM, Jacobs MJ, Goldman M, van den Berg WB. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Arthritis Rheum 1997; 40: 249–260
   PubMed Web of Science ®Google Scholar
• McIntyre KW, Shuster DJ, Gillooly KM, Warrier RR, Connaughton SE, Hall LB, Arp LH, Gately MK, Magram J. Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur J Immunol 1996; 26: 2933–2938
   PubMed Web of Science ®Google Scholar
• Tada Y, Ho A, Matsuyama T, Mak TW. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J Exp Med 1997; 185: 231–238
   PubMed Web of Science ®Google Scholar
• Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: Interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006; 65(Suppl 3)29–33
   Google Scholar
• Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 246–251
   PubMed Web of Science ®Google Scholar
• Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 296–301
   PubMed Web of Science ®Google Scholar
• Wooley PH, Luthra HS, Krco CJ, Stuart JM, David CS. Type II collagen-induced arthritis in mice. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen. Arthritis Rheum 1984; 27: 1010–1017
   PubMed Web of Science ®Google Scholar
• Hirofuji T, Hori H, Nagai Y, Saisho K, Sumiyoshi A, Koga T. Characterization of monoclonal antibody specific for human type II collagen: Possible implication in collagen-induced arthritis. Clin Exp Immunol 1985; 62: 159–166
   PubMed Web of Science ®Google Scholar
• Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthritis with monoclonal antibodies to collagen. J Immunol 1992; 148: 2103–2108
   PubMed Web of Science ®Google Scholar
• Holmdahl R, Rubin K, Klareskog L, Larsson E, Wigzell H. Characterization of the Ab response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies. Arthritis Rheum 1986; 29: 400–410
   PubMed Web of Science ®Google Scholar
• Kelsoe G. In situ studies of the germinal center reaction. Adv Immunol 1995; 60: 267–288
   PubMed Web of Science ®Google Scholar
• MacLennan ICM. Germinal centers. Annu Rev Immunol 1994; 12: 117–139
   PubMed Web of Science ®Google Scholar
• Liu YJ, Arpin C. Germinal center development. Immunol Rev 1997; 156: 111–126
   PubMed Web of Science ®Google Scholar
• Johansson AC, Hansson AS, Nandakumar KA, Backlund J, Holmdahl R. IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol 2001; 167: 3505–3512
   PubMed Web of Science ®Google Scholar
• Hirofuji T, Kakimoto K, Hori H, Nagai Y, Saisho K, Sumiyoshi A, Koga T. Characterization of monoclonal antibody specific for human type II collagen: Possible implicationin collagen-induced arthritis. Clin Exp Immunol 1985; 62: 159–166
   PubMed Web of Science ®Google Scholar
• Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthritis with monoclonal antibodies to collagen. J Immunol 1992; 148: 2103–2108
   PubMed Web of Science ®Google Scholar
• Holmdahl R, Jansson L, Larsson E, Rubin K, Klareskog K. Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 1986; 29: 106–113
   PubMed Web of Science ®Google Scholar
• Han S, Cao S, Bheekha-Escura R, Zheng B. Germinal center reaction in the joints of mice with collagen-induced arthritis. Arthritis Rheum 2001; 44: 1438–1443
   PubMedGoogle Scholar
• Wolfowicz CB, Sakorafas P, Rothstein TL, Marshak-Rothestein A. Oligoclonality of rheumatoid factors arising spontaneously in lpr/lpr mice. Clin Immunol Immunopath 1988; 46: 382–395
   PubMedGoogle Scholar